Thank you for taking time to provide your feedback to the editors. Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.
Adial Pharmaceuticals (NASDAQ:ADIL) announced the completion of the AD04-103 pharmacokinetics (PK) study for AD04, confirming ...
It is very difficult to determine the duration of action of 5-HT 3-receptor antagonists at vagal afferent neuronal receptors. A surrogate test that may have clinical relevance is the duration of ...
AD04 is designed for patients with specific 5-HT3 receptor mutations (SNPs rs1150226-AG or rs1176713-GG), which may enhance drug binding and efficacy. Adial has developed a Companion Diagnostic ...
As a result of these guidelines, and in an attempt to reduce the overall cost of antiemetic therapy, many institutions have adopted strategies to reduce the total dose of 5-HT3-receptor antagonists.
Claiborne: The drug showed strong safety across all of the groups we tested. We knew this going in based on prior studies, but AD04 has also shown higher efficacy among certain patients with certain ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果